Clinical Trial Opportunities

Clinical Trial Opportunities

Clinical Trial Opportunities

If you are interested in being part of a clinical trial, there may be opportunities to learn more and get involved. The National Institutes of Health (NIH) maintains a website where you can look for opportunities. is a database of privately and publicly funded clinical studies that are being conducted around the world. You can find studies that might be relevant for you by searching by disease and country.

For example, two trials in rheumatoid arthritis (RA) are currently being conducted in the US that do not involve testing a new drug: StopRA and TARGET.


StopRA is a research study whose goal is to prevent RA in people who don’t yet have RA, but who are at risk for future RA because of an elevated blood test called CCP. Since RA runs in families we are interested in talking with you and your family more about participating in StopRA and getting tested for CCP. For more information, go to or contact StopRA study coordinator Marie Feser at (303) 724-7510 or [email protected].

Treatments Against RA and Effect on FDG PET-CT: The TARGET Trial

Did you know that rheumatoid arthritis patients have an increased risk of heart attacks and strokes? Could your arthritis medications lower this risk?

The study aims to compare the effect of two different RA treatments on cardiovascular health in patients who are considering a treatment change. The study is recruiting patients who are only taking methotrexate but in whom additional treatment will be added due to a lack of improvement. The trial will randomize participants to take a TNF inhibitor (Enbrel or Humira) in addition to their Methotrexate or to take Triple Therapy (Methotrexate + Sulfasalazine + Hydroxychloroquine). The study will provide you with all trial medications (excluding Methotrexate) for the 6-month duration of the study. Study involvement requires two FDG-PET/CT scans and six follow-up visits over a period of six months.

To participate in the study, you must:

  • Be 45 years or older (men) or 50 years or older (women)
  • Have a diagnosis of rheumatoid arthritis (RA) with moderate disease activity
  • Have taken methotrexate alone for two months and be considering a treatment change

Patients with a prior use of rituximab or with a history of cardiovascular disease are excluded.

More information is available at Interested patients can call the TARGET Central Number at (617)525-7830 or email TARGET Study Coordinator Rachel Broderick at [email protected].